SCHEMBL10315345

SCHEMBL10315345

CC1(C)c2ccccc2-c2ccc(-c3cc4nc(-c5ccc(N(c6ccccc6)c6ccc(-c7nnc(-c8ccccc8)o7)cc6)cc5)c(-c5ccc(N(c6ccccc6)c6ccc(-c7nnc(-c8ccccc8)o7)cc6)cc5)nc4cc3-c3ccc4c(c3)C(C)(C)c3ccccc3-4)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.38
NPC1 O15118 11/20 0.38
SMN1; SMN2 Q16637 9/20 0.38
ALDH1A1 P00352 7/20 0.38
HPGD P15428 7/20 0.38
KDM4E B2RXH2 5/20 0.38
GAA P10253 1/20 0.38
LMNA P02545 2/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 1/20 0.37
USP2 O75604 1/20 0.37
KMT2A Q03164 1/20 0.37
RXFP1 Q9HBX9 2/20 0.37
TSHR P16473 3/20 0.36
ATR Q13535 7/20 0.36
NFKB1 P19838 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10315106 1.00 RAB9A (0.38) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315128 0.94 ALDH1A1 (0.39) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315107 0.92 RAB9A (0.38) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315344 0.92 RAB9A (0.38) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL12721941 0.92 RAB9A (0.45) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL12722093 0.92 RAB9A (0.45) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315375 0.91 RAB9A (0.38) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315150 0.91 RAB9A (0.38) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315349 0.90 RAB9A (0.36) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD
SCHEMBL10315109 0.90 RAB9A (0.36) RAB9ANPC1SMN1; SMN2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2067778-B1 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LAB (JP) 2016-08-17 EP disclosed
US-8216696-B2 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-07-10 US disclosed
US-8216696-B2 Quinoxaline derivative, and light emitting element, light emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-07-10 US disclosed
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-18 US disclosed
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2009-06-18 US disclosed
EP-2067778-A1 Quinoxaline derivative, and light emitting element, licht emitting device and electronic appliance using the same SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-06-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090153041-A1 Quinoxaline Derivative, and Light Emitting Element, Light Emitting Device and Electronic Appliance Using the Same SLC1A2, SLC18A2, SLC18A3 RAB9A 979/4885NPC1 3369/4885SMN1; SMN2 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.